2017 American Transplant Congress
Influenza Viral Dynamics in a Large Cohort of Transplant Patients with Natural Influenza Infection.
Background:Influenza infection significantly impacts transplant patients. Despite this, there are limited data on how virological characteristics, including influenza viral load (VL), impact the outcome of…2017 American Transplant Congress
A Single Center's Experience of Direct Acting Anti-Viral Agents in HCV Positive Patients Receiving an HCV Positive Kidney.
Background: Nearly 8% of patients in the U.S. undergoing hemodialysis are Hepatitis C (HCV) positive. There is a survival benefit in HCV positive patients who…2017 American Transplant Congress
Mutations in Influenza A Virus and Clinical Implications in Transplant Recipients.
1UHN, Toronto, Canada; 2REIPI, Seville, Spain; 3UPenn, Philadelphia; 4LUMC, Leiden, Netherlands
Background: Organ and hematopoietic stem cell transplant (HSCT) recipients are predisposed to complications of influenza infection and as such may constitute an important source of…2017 American Transplant Congress
Hepatitis E Virus-Associated Cryoglobulinemia in Solid-Organ-Transplant Recipients: A Prospective Study.
Hepatitis E virus (HEV) is responsible for acute and chronic autochthonous hepatitis in developed countries, particularly in Western Europe. Conversely to hepatitis B or C,…2017 American Transplant Congress
Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.
Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…2017 American Transplant Congress
Low Dose Valganciclovir for CMV Prophylaxis in the First Year of Kidney Transplantation.
1Pharmacy, University of Colorado, Aurora, CO; 2Nephrology, University of Colorado, Aurora
Valganciclovir (VGC) is the standard antiviral agent used for the prevention of CMV diseases in moderate and high risk renal transplant recipients, yet the optimal…2017 American Transplant Congress
Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.
Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…2016 American Transplant Congress
Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(-) and HBcAb(+) After Kidney Transplantation?
Background Hepatitis B virus(HBV) infection is common among uremia patients in China. Many patients received kidney transplantation are occult HBV carriers with HBsAg(-) and HBcAb(+)…2016 American Transplant Congress
Descriptive Epidemiology and Trends of Community Parenteral Antimicrobial Therapy Utilization Among Solid Organ Transplant Recipients at a High Volume Transplant Center 2008 to 2014.
Infectious Diseases, Cleveland Clinic, Cleveland, OH.
INTRODUCTION: Solid organ transplant (SOT) recipients may benefit from community-based parenteral anti-infective therapy (CoPAT). Limited data are available. CoPAT may help reduce LOS. As a…2016 American Transplant Congress
Is SVR Associated with Improved Hepatic Function in Hepatitis C Gen 1 Pts with Cirrhosis 1 Year After Completing Treatment with Sofosbuvir + Simeprevir +/- Ribavirin?
Background: Combination antiviral therapy involving Sofosbuvir (SOF) & Simeprevir (SIM) +/- Ribavirin (RBV) is a relatively safe & effective Tx option in pts with gen…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- 14
- Next Page »